Cannabinol (CBN) Research Dashboard
Double-blind human trials
Clinical human trials
What am I missing as a non-subscriber?
To see a full dashboard with study details and filtering, go to our DEMO page.
As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.
CannaKeys has 81 studies associated with Cannabinol (CBN).
Here is a small sampling of Cannabinol (CBN) studies by title:
- Cannabinol inhibits oxytosis/ferroptosis by directly targeting mitochondria independently of cannabinoid receptors
- Cannabinol modulates neuroprotection and intraocular pressure: A potential multi-target therapeutic intervention for glaucoma
- Fetal Exposure to Cannabis and Childhood Metabolic Outcomes: The Healthy Start Study
- Cannabinoids, Insomnia, and Other Sleep Disorders
- Pilot clinical and pharmacokinetic study of Δ9-Tetrahydrocannabinol (THC)/Cannabidiol (CBD) nanoparticle oro-buccal spray in patients with advanced cancer experiencing uncontrolled pain
Components of the Cannabinol (CBN) Research Dashboard
- Top medical conditions associated with Cannabinol (CBN)
- Proven effects in clinical trials for Cannabinol (CBN)
- Receptors associated with Cannabinol (CBN)
- Individual study details for Cannabinol (CBN)
Ready to become a subscriber? Go to our PRICING page.
Members can filter by the following criteria:
- Study Type
- Organ Systems
- Study Result
- Year of Publication
Overview - Cannabinol (CBN)
Description of Cannabinol (CBN)
The plant-based (phytocannabinoid) Cannabinol was discovered in 1896 (by Wood, Spivey, and Easterfield) and its chemical structure was determined in 1940 (by Roger Adams). By 2016 there were 13 members in the CBN group. Most CBN found in cannabis plant material is due to chemical changes that naturally occur during the drying process. As THC begins to degrade over time, some of its chemical composition transforms into CBN. Research seems to indicated that CBN promotes sedation even at low concentrations. CBN is not a mind-altering cannabinoid or at best is a very mild psychoactive compound.
Cannabinolum, Cannabinolo, and others.
IUPAC Name: 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol
Molecular Formula: C21H26O2
Cannabinol (CBN) Properties and Effects
• Anti-bacterial against MRSA
• Appetite stimulant
• Epidermolysis bullosa
Cannabinol (CBN) Receptor Binding
Endocannabinoid system (ECS)
• Agonist at CB1 (~ten times lower than delta-9-THC; Chiara Maioli et al. 2022)
• Agonist at CB2 (mixed results suggesting equal to ~3 times lower than delta-9-THC; Chiara Maioli et al. 2022)
Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.
Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.